Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lisziewicz

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|August 16, 1994
Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cellsJ Lisziewicz, D Sun, F F Weichold, et al.
AIDS Research and Human Retroviruses|October 9, 1999
Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parametersF Lori, E Rosenberg, J Lieberman, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 26, 1994
A Rev-inducible mutant gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infectionJ A Smythe, D Sun, M Thomson, et al.
AIDS Research and Human Retroviruses|July 1, 1995
Antisense phosphorothioate oligodeoxynucleotides alter HIV type 1 replication in cultured human macrophages and peripheral blood mononuclear cellsF F Weichold, J Lisziewicz, R A Zeman, et al.
Journal of Virology|November 1, 1993
Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive elementG Li, J Lisziewicz, D Sun, et al.
The Journal of Infectious Diseases|November 24, 1999
Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoirF Lori, H Jessen, J Lieberman, et al.
Gene Therapy|July 5, 2001
SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promotersG C Jayan, P Cordelier, C Patel, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1993
Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDSJ Lisziewicz, D Sun, J Smythe, et al.
Journal of Virology|July 20, 2001
Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cellsJ Lisziewicz, D I Gabrilovich, G Varga, et al.
Science (New York, N.Y.)|November 25, 2000
Control of SIV rebound through structured treatment interruptions during early infectionF Lori, M G Lewis, J Xu, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Proceedings of the National Academy of Sciences of the United States of America|August 16, 1994
Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cellsJ Lisziewicz, D Sun, F F Weichold, et al.
AIDS Research and Human Retroviruses|October 9, 1999
Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parametersF Lori, E Rosenberg, J Lieberman, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 26, 1994
A Rev-inducible mutant gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infectionJ A Smythe, D Sun, M Thomson, et al.
AIDS Research and Human Retroviruses|July 1, 1995
Antisense phosphorothioate oligodeoxynucleotides alter HIV type 1 replication in cultured human macrophages and peripheral blood mononuclear cellsF F Weichold, J Lisziewicz, R A Zeman, et al.
Journal of Virology|November 1, 1993
Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive elementG Li, J Lisziewicz, D Sun, et al.
The Journal of Infectious Diseases|November 24, 1999
Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoirF Lori, H Jessen, J Lieberman, et al.
Gene Therapy|July 5, 2001
SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promotersG C Jayan, P Cordelier, C Patel, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1993
Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDSJ Lisziewicz, D Sun, J Smythe, et al.
Journal of Virology|July 20, 2001
Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cellsJ Lisziewicz, D I Gabrilovich, G Varga, et al.
Science (New York, N.Y.)|November 25, 2000
Control of SIV rebound through structured treatment interruptions during early infectionF Lori, M G Lewis, J Xu, et al.
Pageof 6